Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal International Journal of Health, Engineering and Technology
Wahyu Kurniawan
a:1:{s:5:"en_US";s:22:"Universitas Airlangga ";}
Agriculture, Biological Sciences & Forestry Chemical Engineering, Chemistry & Bioengineering Dentistry Engineering Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Mechanical Engineering Medicine & Pharmacology Nursing Public Health Veterinary

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Cost-Effectiveness Analysis Of Metformin Use In Type 2 Diabetes Mellitus Patients In Hospitals: A Systematic Literature Review Wahyu Kurniawan; Thinni Nurul Rochmah
International Journal of Health Engineering and Technology Vol. 5 No. 1 (2026): IJHET MAY 2026
Publisher : CV. AFDIFAL MAJU BERKAH

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55227/ijhet.v5i1.763

Abstract

Type 2 diabetes mellitus (T2DM) places a significant economic burden on Indonesia, necessitating the selection of cost-effective pharmacological therapies. Metformin has long been recommended as first-line therapy, but evidence of its cost-effectiveness across Indonesian hospitals remains fragmented and methodologically diverse. This study aimed to conduct a systematic review and synthesize evidence regarding the cost-effectiveness of metformin use in T2DM patients in Indonesian hospitals. The study used a systematic literature review design based on the PRISMA framework. Articles published since 2020 and obtained from Google Scholar, PubMed, and Publish or Perish were assessed using the PICO criteria (Population: T2DM patients in hospital; Intervention: metformin; other antidiabetic therapies; Outcome: cost-effectiveness). In total, six national studies were selected, covering both inpatient and outpatient settings. Data were extracted descriptively, while cost-effectiveness results (primarily the Average Cost-Effectiveness Ratio/ACER) were analyzed narratively. Across all reviewed studies, metformin consistently demonstrated lower ACER values ​​than comparator therapies (e.g., glibenclamide, glimepiride, gliquidone, and acarbose-based combinations), suggesting better cost-efficiency with equivalent or higher clinical effectiveness. Conclusion: Metformin is a cost-effective first-line therapy for T2DM patients in Indonesian hospitals, making it worthy of being maintained as the primary choice in clinical practice and hospital formularies.
Co-Authors Thinni Nurul Rochmah